Evidence map›Paper›PMID 32046188›Full record

ReviewCells2020

The Role of TRPC1 in Modulating Cancer Progression.

Osama M Elzamzamy, Reinhold Penner, Lori A Hazlehurst

Open access · goldAbstract readReview
In one paragraph

Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. TRP Channels in Skin Cancer: Focus on Malignant Melanoma.International journal of molecular sciences · 2025
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Role of TRP Channels in Metabolism-Related Diseases.International journal of molecular sciences · 2024
    Review
  17. Article
  18. The odyssey of the TR(i)P journey to the cellular membrane.Frontiers in cell and developmental biology · 2024
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Osama M ElzamzamyClinical and Translational Sciences Institute, School of Medicine, West Virginia University, Morgantown, WV 26506, USA.
Reinhold PennerThe Queen's Medical Center and University of Hawaii, Honolulu, HI 96813, USA.
Lori A HazlehurstPharmaceutical Sciences, School of Pharmacy and WVU Cancer Institute, West Virginia University, Morganton, WV 26506, USA.
West Virginia University · USUniversity of Hawaiʻi at Mānoa · US

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Anne Courtney DeVries · 2012 to 2026
$81.0M
Mechanism underpinning synergy with combined treatment of MTI-101 and Dexamethasone in Multiple MyelomaR44CA221554 · NCI · MODULATION THERAPEUTICS, INC. · PI HAZLEHURST, LORI · 2017 to 2020
$2.4M
Targeting CD44-mediated calcium signaling for the treatment of relapsed myelomaR01CA195727 · NCI · WEST VIRGINIA UNIVERSITY · PI HAZLEHURST, LORI A · 2015 to 2019
$1.7M
NCI NIH HHS R01 CA195727NCI NIH HHS R44 CA221554NIGMS NIH HHS U54 GM104942
6 · The paper itself

Abstract

Calcium ions (Ca

Indexed as

Disease ProgressionCalcium SignalingEpithelial-Mesenchymal TransitionHumansNeoplasmsTreatment OutcomeTRPC Cation ChannelsTRPC Cation Channelscancer progressionEMTSOCETRPC1

Identifiers

PMID32046188
PMCPMC7072717
OpenAlexW3005452535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.